Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2777830 | 1.00 | IDO1 (0.50) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL2777539 | 1.00 | IDO1 (0.50) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL1705439 | 0.86 | IDO1 (0.53) | IDO1PDPK1 | |
| SCHEMBL1735441 | 0.86 | IDO1 (0.53) | IDO1PDPK1 | |
| SCHEMBL1735423 | 0.86 | IDO1 (0.53) | IDO1PDPK1 | |
| SCHEMBL11671198 | 0.75 | SRD5A1 (0.55) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL9179507 | 0.75 | HTR2A (0.52) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL11569221 | 0.74 | PLAU (0.52) | IDO1PDPK1 | |
| SCHEMBL10633202 | 0.73 | IDO1 (0.52) | IDO1PDPK1CYP11B2RETHTR2A | |
| Magnesium SCHEMBL31510119 | 0.73 | SRD5A1 (0.53) | IDO1PDPK1CYP11B2RETHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199542-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-20 | — | — | US | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| CN-117043140-A | Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidal active substances | 拜耳公司 | 2023-11-10 | — | — | CN | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | claimed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | claimed |
| EP-1948629-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-30 | — | — | EP | claimed |
| EP-1791845-A2 | FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS | AMGEN INC. (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | claimed |
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | claimed |
| EP-1677830-A2 | ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | Amgen Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | claimed |
| US-20050215470-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2005-09-29 | — | — | US | claimed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | claimed |
| WO-2005042027-A2 | ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | AMGEN INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | claimed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | claimed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | claimed |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2002-05-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | LCK, NFATC1, MINK1 | IDO1 12/4885PDPK1 155/4885CYP11B2 723/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | IDO1 3872/4885PDPK1 3215/4885CYP11B2 2250/4885 |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | IDO1 2053/4885PDPK1 816/4885CYP11B2 2805/4885 |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DNPEP, LNPEP, NPEPPS | IDO1 560/4885PDPK1 4589/4885CYP11B2 3420/4885 |
| US-20050215470-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, OPRL1 | IDO1 1647/4885PDPK1 3569/4885CYP11B2 2323/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | IDO1 2561/4885PDPK1 1812/4885CYP11B2 1404/4885 |
| US-20240199542-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | HPD, DDT, PPOX | IDO1 274/4885PDPK1 620/4885CYP11B2 263/4885 |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | GPR4, GPR88, GPR35 | IDO1 3973/4885PDPK1 1290/4885CYP11B2 485/4885 |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | IDO1 3070/4885PDPK1 3391/4885CYP11B2 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.